EUVIMEDEUVIMED entdecken
Crossref

Comparing the Cost of Administering and Monitoring Vancomycin and Daptomycin Through a Home Infusion Pharmacy

Katherine Yang, Wendy Morimoto, Kristina Wong, Mehrnaz Zahiri, Meredith Silverman

Infusion Journal · 2024

DOI: 10.70776/jecb9600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infusion Journal, 2024. Verfasst von Katherine Yang und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study evaluates the cost differences between administering and monitoring vancomycin and daptomycin in a home infusion pharmacy (HIP) setting. Both antibiotics are widely used for treating methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive infections in outpatient parenteral antibiotic therapy (OPAT), but vancomycin requires more intensive therapeutic monitoring than daptomycin. The study aims to quantify pharmacist time spent monitoring patients, lab costs, and overall drug administration costs associated with each therapy in a HIP serving 16 medical centers in Northern California.

Methods

Using a retrospective chart review of 113 patients who received either vancomycin or daptomycin between August and December 2022, the study compares pharmacist time spent, drug and administration device costs, and laboratory costs for each therapy.

Results

Results show that while pharmacist time spent per note was similar for both antibiotics, vancomycin patients required significantly more notes per therapy day, resulting in higher monitoring costs. The average daily pharmacist time and associated costs for vancomycin were significantly higher than for daptomycin ($37.99 vs. $22.60 per day). Additionally, vancomycin required more frequent and expensive lab tests, leading to higher laboratory costs ($14.01 vs. $5.24 per day).

Discussion

The overall cost per therapy day for vancomycin was significantly higher than for daptomycin ($84.56 vs. $59.75), largely due to increased pharmacist time and lab costs, despite the similar cost of drug and administration devices. The study highlights the potential cost savings of using daptomycin over vancomycin in a home infusion setting, particularly for uncomplicated infections. However, limitations include the exclusion of complex clinical scenarios and the potential variation in costs across different health care systems.

Conclusions

These findings suggest that daptomycin may be a more cost-effective alternative to vancomycin for home-based therapy, prompting further evaluation of clinical practices and resource allocation in HIP services.

Zitieren

APA

Yang, K., Morimoto, W., Wong, K., Zahiri, M., & Silverman, M. (2024). Comparing the Cost of Administering and Monitoring Vancomycin and Daptomycin Through a Home Infusion Pharmacy. Infusion Journal. https://doi.org/10.70776/jecb9600

Vancouver

Yang K, Morimoto W, Wong K, Zahiri M, Silverman M. Comparing the Cost of Administering and Monitoring Vancomycin and Daptomycin Through a Home Infusion Pharmacy. Infusion Journal. 2024. doi:10.70776/jecb9600

BibTeX
@article{Yang2024,
  author = {Yang, Katherine and Morimoto, Wendy and Wong, Kristina and Zahiri, Mehrnaz and Silverman, Meredith},
  title = {Comparing the Cost of Administering and Monitoring Vancomycin and Daptomycin Through a Home Infusion Pharmacy},
  journal = {Infusion Journal},
  year = {2024},
  doi = {10.70776/jecb9600}
}
Kostenlos starten →